Literature DB >> 8667094

New method to predict patients' intravenous heparin dose requirements.

B M Reilly1, R A Raschke.   

Abstract

OBJECTIVE: To predict intravenous heparin dose requirements of patients treated for thromboembolic disorders.
DESIGN: A retrospective cohort study in which we used simple linear regression to predict patients' effective maintenance dose (EMD) of heparin (units/kg/hour needed to achieve and maintain APTT therapeutic range) from patients' "heparin responsiveness" (the APTT increase after the initial 6 hours of heparin treatment per units/kg/hour received). SETTING/PATIENTS: The model was derived from 46 patients treated at one hospital (Hospital A) and then tested in 42 patients treated at another hospital (Hospital B).
MEASUREMENTS AND MAIN RESULTS: Among Hospital A patients, there was a strong linear correlation (r = -.880; p < .001) between EMD (mean 16.02 units/kg/hour; 95% CI 14.9, 17.15) and "heparin responsiveness" (HR): EMD = 25.651 - [95.118 x HR]. This model accurately predicted Hospital B patients' EMD: 97% (37/38) fell within the model's 95% prediction interval; the mean absolute difference between predicted and actual EMD was 1.73 units/kg/hour (95% CI 1.39, 2.08); and only 16% of patients had EMD's more than 3 units/kg/hour different from that predicted by the regression model. The model's accuracy was comparable to that of our gold standard, the weight-based heparin dosing nomogram.
CONCLUSION: The infusion dose of intravenous heparin effective for an individual patient can be predicted accurately from the patient's body weight and APTT response to the initial 6 hours of treatment. Especially in hospitals where validated heparin dosing nomograms are not used, clinicians may find this simple technique useful in achieving timely therapeutic anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667094     DOI: 10.1007/bf02600270

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  35 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

2.  Adjusting heparin infusion rates from the initial response to activated coagulation time.

Authors:  P G Hattersley; J C Mitsuoka; R J Ignoffo; J H King; N A Musallam
Journal:  Drug Intell Clin Pharm       Date:  1983-09

3.  Audit of control of heparin treatment.

Authors:  A G Fennerty; P Thomas; G Backhouse; P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

4.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

5.  Heparin kinetics in venous thrombosis and pulmonary embolism.

Authors:  J Hirsh; W G van Aken; A S Gallus; C T Dollery; J F Cade; W L Yung
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

6.  Heparin kinetics: variables related to disposition and dosage.

Authors:  R J Cipolle; R D Seifert; B A Neilan; D E Zaske; E Haus
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

7.  Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences.

Authors:  L R Whitfield; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

Review 8.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

Authors:  C S Landefeld; R J Beyth
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

9.  Heparin pharmacokinetics: increased requirements in pulmonary embolism.

Authors:  T L Simon; T M Hyers; J P Gaston; L A Harker
Journal:  Br J Haematol       Date:  1978-05       Impact factor: 6.998

10.  Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction.

Authors:  A G Turpie; J G Robinson; D J Doyle; A S Mulji; G J Mishkel; B J Sealey; J A Cairns; L Skingley; J Hirsh; M Gent
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

View more
  1 in total

Review 1.  Listening for the therapeutic window: Advances in drug delivery utilizing photoacoustic imaging.

Authors:  Colman Moore; Fang Chen; Junxin Wang; Jesse V Jokerst
Journal:  Adv Drug Deliv Rev       Date:  2019-07-08       Impact factor: 15.470

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.